Sees Q3 revenue $386M-$390M, consensus $388.59M, representing reported growth of 0.2%-1.3% and organic growth of 0.3% to 1.3%. Adjusted EPS view includes the impact of the Boston recall.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences Reports Second Quarter 2023 Financial Results
- Integra Lifesciences (IART) Q2 Earnings Cheat Sheet
- Integra LifeSciences price target raised to $48 from $44 at Truist
- Integra LifeSciences upgraded to Buy from Hold at Jefferies
- Integra LifeSciences to Host Second Quarter 2023 Financial Results Conference Call on July 27, 2023
